Sionna Therapeutics Inc (SION) Stock Price, Quote & News

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 819 2020

Website: www.sionnatx.com

Address:

21 Hickory Drive, Suite 500, Waltham, United States

theflynews Dec. 1 at 9:37 PM

What You Missed On Wall Street On Monday - $SION - https://thefly.com/permalinks/entry.php/SIONid4248109?1764624879C38

0 · Reply

medguy Dec. 1 at 7:17 PM

Out with some gains thank you $SION love you

0 · Reply

CH_Expat Dec. 1 at 6:40 PM

$ORKA $SION Very interested after a healthy correction.

0 · Reply

medguy Dec. 1 at 5:04 PM

Looking for a bounce $SION

0 · Reply

DARKP00L Dec. 1 at 4:40 PM

$SION 11:21 on Dec. 01 2025 Sionna Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform. #tradeideas

0 · Reply

JarvisFlow Dec. 1 at 2:28 PM

RBC Capital has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Underperform with a target price of 24.

0 · Reply

JarvisFlow Nov. 19 at 10:13 AM

BTIG has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Buy with a target price of 50.

1 · Reply

d_risk Nov. 5 at 4:19 PM

$SION - Sionna Therapeutics, Inc. - 10Q - Updated Risk Factors SION’s updated 10-Q risk factors stress heightened uncertainty in clinical trial outcomes, regulatory hurdles, post-approval safety, manufacturing and IP challenges, evolving healthcare laws, and fierce competition—while streamlining or removing detail on orphan drug incentives, personnel, and operational growth risks. #Biotechnology #HealthcareLaws #ManufacturingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/SION/10-Q/2025-11-05

0 · Reply

shark1989 Oct. 27 at 2:05 PM

$SION Looking for a 5% push today!

0 · Reply

S_Franconi Oct. 22 at 1:11 PM

$SION Sionna’s ongoing clinical trials, including a Phase 1b trial for SION-451 combinations and a future Phase 2a trial for SION-719, are key catalysts that could validate their approach and potentially lead to significant market adoption. https://www.tipranks.com/news/ratings/buy-rating-for-sionna-therapeutics-innovative-cystic-fibrosis-treatments-with-promising-clinical-trials-ratings

1 · Reply

Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 24, 2025, 7:00 AM EST - 12 days ago

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Oct 24, 2025, 1:15 PM EDT - 6 weeks ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Oct 21, 2025, 7:00 AM EDT - 6 weeks ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Oct 1, 2025, 4:05 PM EDT - 2 months ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Sep 10, 2025, 9:00 AM EDT - 3 months ago

Stock Picks From Seeking Alpha's August 2025 New Analysts

ASML CLF ENPH ESEA FRSH FTK GDX

Sep 8, 2025, 11:13 AM EDT - 3 months ago

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:00 AM EDT - 3 months ago

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 3 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Aug 11, 2025, 7:00 AM EDT - 4 months ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Jun 6, 2025, 11:00 AM EDT - 6 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 4, 2025, 7:00 AM EDT - 6 months ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 3, 2025, 7:00 AM EDT - 6 months ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 12, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Mar 20, 2025, 7:00 AM EDT - 9 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 10 months ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 10, 2025, 4:03 PM EST - 10 months ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 8, 2025, 2:30 AM EST - 10 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AARD AGH EPWK FBGL HCAI KRMN NPB

Feb 6, 2025, 7:51 PM EST - 10 months ago

Sionna Therapeutics Prices Upsized Initial Public Offering

Feb 1, 2025, 2:10 AM EST - 11 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE MTSR ODTX ODYS

Jan 24, 2025, 1:45 PM EST - 11 months ago

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

theflynews Dec. 1 at 9:37 PM

What You Missed On Wall Street On Monday - $SION - https://thefly.com/permalinks/entry.php/SIONid4248109?1764624879C38

0 · Reply

medguy Dec. 1 at 7:17 PM

Out with some gains thank you $SION love you

0 · Reply

CH_Expat Dec. 1 at 6:40 PM

$ORKA $SION Very interested after a healthy correction.

0 · Reply

medguy Dec. 1 at 5:04 PM

Looking for a bounce $SION

0 · Reply

DARKP00L Dec. 1 at 4:40 PM

$SION 11:21 on Dec. 01 2025 Sionna Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform. #tradeideas

0 · Reply

JarvisFlow Dec. 1 at 2:28 PM

RBC Capital has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Underperform with a target price of 24.

0 · Reply

JarvisFlow Nov. 19 at 10:13 AM

BTIG has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Buy with a target price of 50.

1 · Reply

d_risk Nov. 5 at 4:19 PM

0 · Reply

shark1989 Oct. 27 at 2:05 PM

$SION Looking for a 5% push today!

0 · Reply

S_Franconi Oct. 22 at 1:11 PM

1 · Reply

S_Franconi Oct. 22 at 12:17 PM

$SION 46 Watchers. 10/22/25

0 · Reply

topstockalerts Oct. 21 at 11:46 PM

Top Gainers PT2 $ATMV $BOF $SION $YDKG $NAUT

0 · Reply

topstockalerts Oct. 21 at 8:13 PM

Top Gainers PT2 $ATMV $BOF $SION $RANI $AGRZ

0 · Reply

extrodyne Oct. 21 at 8:00 PM

$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.

0 · Reply

patb99 Oct. 21 at 7:25 PM

$SION 😮

1 · Reply

DARKP00L Oct. 21 at 5:26 PM

$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas

0 · Reply

S_Franconi Oct. 21 at 5:14 PM

$SION https://apps.cff.org/trials/pipeline/

0 · Reply

S_Franconi Oct. 21 at 5:11 PM

$SION Thank you Sion!

0 · Reply

Doozio Oct. 21 at 4:01 PM

$SION under radar 💎. Barring a faatch 💣. 🐒🍌🧠⏰♾️

0 · Reply

S_Franconi Oct. 21 at 2:53 PM

$SION Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-announces-initiation-precision-cf-phase-2a

0 · Reply

DARKP00L Oct. 21 at 11:14 AM

$SION 07:12 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a POC Trial Evaluating SION-719, NBD1 Stabilizer, When Added To Trikafta, Current Standard Of Care In CF; Topline Data Expected In Mid-2026 #tradeideas

0 · Reply

DARKP00L Oct. 21 at 11:13 AM

$SION 07:04 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a Proof-Of-Concept Trial Of SION-719 #tradeideas

0 · Reply

Market Cap	1.82B
Revenue (ttm)	0.00
Net Income (ttm)	-61.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	211,500
Avg Vol	299,324
Day's Range	N/A - N/A
Shares Out	44.63M
Stochastic %K	51%
Beta	N/A
Analysts	Strong Sell
Price Target	$42.33